96 related articles for article (PubMed ID: 20834076)
21. The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study.
Salvucci O; Bouchard A; Baccarelli A; Deschênes J; Sauter G; Simon R; Bianchi R; Basik M
Breast Cancer Res Treat; 2006 Jun; 97(3):275-83. PubMed ID: 16344916
[TBL] [Abstract][Full Text] [Related]
22. Expression of metallothionein in invasive ductal breast cancer in relation to prognosis.
Zhang R; Zhang H; Wei H; Luo X
J Environ Pathol Toxicol Oncol; 2000; 19(1-2):95-7. PubMed ID: 10905514
[TBL] [Abstract][Full Text] [Related]
23. Immunolocalization of BRCA1 protein in tumor breast tissue: prescreening of BRCA1 mutation in Tunisian patients with hereditary breast cancer?
Troudi W; Uhrhammer N; Ben Romdhane K; Sibille C; Mahfoudh W; Chouchane L; Ben Ayed F; Bignon YJ; Ben Ammar Elgaaied A
Eur J Histochem; 2007; 51(3):219-26. PubMed ID: 17921118
[TBL] [Abstract][Full Text] [Related]
24. Expression of cyclooxygenase-2 in breast carcinogenesis and its relation to HER-2/neu and p53 protein expression in invasive ductal carcinoma.
Cho MH; Yoon JH; Jaegal YJ; Choi YD; Lee JS; Lee JH; Nam JH; Choi C; Lee MC; Park CS; Woo Juhng S; Min KW
Breast; 2006 Jun; 15(3):390-8. PubMed ID: 16169726
[TBL] [Abstract][Full Text] [Related]
25. Reduction of BRCA1 protein expression in Japanese sporadic breast carcinomas and its frequent loss in BRCA1-associated cases.
Yoshikawa K; Honda K; Inamoto T; Shinohara H; Yamauchi A; Suga K; Okuyama T; Shimada T; Kodama H; Noguchi S; Gazdar AF; Yamaoka Y; Takahashi R
Clin Cancer Res; 1999 Jun; 5(6):1249-61. PubMed ID: 10389907
[TBL] [Abstract][Full Text] [Related]
26. Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables.
Depowski PL; Rosenthal SI; Brien TP; Stylos S; Johnson RL; Ross JS
Mod Pathol; 2000 May; 13(5):542-7. PubMed ID: 10824926
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers.
Palacios J; Honrado E; Osorio A; Cazorla A; Sarrió D; Barroso A; Rodríguez S; Cigudosa JC; Diez O; Alonso C; Lerma E; Sánchez L; Rivas C; Benítez J
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3606-14. PubMed ID: 14506147
[TBL] [Abstract][Full Text] [Related]
28. Increased progesterone receptor expression in benign epithelium of BRCA1-related breast cancers.
King TA; Gemignani ML; Li W; Giri DD; Panageas KS; Bogomolniy F; Arroyo C; Olvera N; Robson ME; Offit K; Borgen PI; Boyd J
Cancer Res; 2004 Aug; 64(15):5051-3. PubMed ID: 15289302
[TBL] [Abstract][Full Text] [Related]
29. HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry.
Quenneville LA; Phillips KA; Ozcelik H; Parkes RK; Knight JA; Goodwin PJ; Andrulis IL; O'Malley FP
Cancer; 2002 Nov; 95(10):2068-75. PubMed ID: 12412159
[TBL] [Abstract][Full Text] [Related]
30. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer.
Prati R; Apple SK; He J; Gornbein JA; Chang HR
Breast J; 2005; 11(6):433-9. PubMed ID: 16297088
[TBL] [Abstract][Full Text] [Related]
31. Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients.
Sharma G; Mirza S; Parshad R; Srivastava A; Gupta SD; Pandya P; Ralhan R
Life Sci; 2010 Jul; 87(3-4):83-91. PubMed ID: 20470789
[TBL] [Abstract][Full Text] [Related]
32. BRCA1 protein expression and its correlation with ER/PR status in sporadic and familial breast cancer in Eastern Indian patients--a hospital based study.
Ashraf M; Jha JK; Mukherjee N; Panda CK; Nayak S; Jadhav TS; Dikshit N; Nath NC; Chakraborty J; Biswas J
J Indian Med Assoc; 2011 Dec; 109(12):873-8. PubMed ID: 23469566
[TBL] [Abstract][Full Text] [Related]
33. Effect of BRCA1 immunohistochemical localizations on prognosis of patients with sporadic breast carcinomas.
Mylona E; Melissaris S; Nomikos A; Theohari I; Giannopoulou I; Tzelepis K; Nakopoulou L
Pathol Res Pract; 2014 Aug; 210(8):533-40. PubMed ID: 24947414
[TBL] [Abstract][Full Text] [Related]
34. [Immunohistochemical investigation of steroid hormones (ER, PR) in breast cancer].
Mchedlishvili MIu; Gabunia UA; Makharoblidze ER; Burnadze KT; Piradashvili DZ
Georgian Med News; 2005 Feb; (119):65-7. PubMed ID: 15834186
[TBL] [Abstract][Full Text] [Related]
35. Expression of BRCA1, HER-1 (EGFR) and HER-2 in sporadic breast cancer and relationships to other clinicopathological prognostic features.
Ansquer Y; Mandelbrot L; Lehy T; Salomon L; Dhainaut C; Madelenat P; Feldmann G; Walker F
Anticancer Res; 2005; 25(6C):4535-41. PubMed ID: 16334138
[TBL] [Abstract][Full Text] [Related]
36. BRCA-associated breast cancer: absence of a characteristic immunophenotype.
Robson M; Rajan P; Rosen PP; Gilewski T; Hirschaut Y; Pressman P; Haas B; Norton L; Offit K
Cancer Res; 1998 May; 58(9):1839-42. PubMed ID: 9581822
[TBL] [Abstract][Full Text] [Related]
37. Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers.
van der Groep P; van Diest PJ; Menko FH; Bart J; de Vries EG; van der Wall E
J Clin Pathol; 2009 Oct; 62(10):926-30. PubMed ID: 19541683
[TBL] [Abstract][Full Text] [Related]
38. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma.
Ariga R; Zarif A; Korasick J; Reddy V; Siziopikou K; Gattuso P
Breast J; 2005; 11(4):278-80. PubMed ID: 15982396
[TBL] [Abstract][Full Text] [Related]
39. HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis.
Tsiambas E; Karameris A; Dervenis C; Lazaris AC; Giannakou N; Gerontopoulos K; Patsouris E
JOP; 2006 May; 7(3):283-94. PubMed ID: 16685109
[TBL] [Abstract][Full Text] [Related]
40. High-risk human papilloma virus infection, tumor pathophenotypes, and BRCA1/2 and TP53 status in juvenile breast cancer.
Aceto GM; Solano AR; Neuman MI; Veschi S; Morgano A; Malatesta S; Chacon RD; Pupareli C; Lombardi M; Battista P; Marchetti A; Mariani-Costantini R; Podestà EJ
Breast Cancer Res Treat; 2010 Aug; 122(3):671-83. PubMed ID: 19851859
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
